GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VYNE Therapeutics Inc (NAS:VYNE) » Definitions » Price-to-Tangible-Book

VYNE (VYNE Therapeutics) Price-to-Tangible-Book : 0.59 (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is VYNE Therapeutics Price-to-Tangible-Book?

As of today (2024-12-11), VYNE Therapeutics's share price is $2.55. VYNE Therapeutics's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $4.31. Hence, VYNE Therapeutics's Price to Tangible Book Ratio of today is 0.59.

The historical rank and industry rank for VYNE Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

VYNE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.28   Med: 1.18   Max: 10.85
Current: 0.59

During the past 9 years, VYNE Therapeutics's highest Price to Tangible Book Ratio was 10.85. The lowest was 0.28. And the median was 1.18.

VYNE's Price-to-Tangible-Book is ranked better than
93.27% of 1203 companies
in the Biotechnology industry
Industry Median: 2.9 vs VYNE: 0.59

A closely related ratio is called PB Ratio. As of today, VYNE Therapeutics's share price is $2.55. VYNE Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2024 was $4.31. Hence, VYNE Therapeutics's P/B Ratio of today is 0.59.


VYNE Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for VYNE Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VYNE Therapeutics Price-to-Tangible-Book Chart

VYNE Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only 2.47 7.28 1.12 0.28 0.37

VYNE Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 0.37 0.53 0.38 0.44

Competitive Comparison of VYNE Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, VYNE Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VYNE Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where VYNE Therapeutics's Price-to-Tangible-Book falls into.



VYNE Therapeutics Price-to-Tangible-Book Calculation

VYNE Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=2.55/4.307
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


VYNE Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of VYNE Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


VYNE Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
685 Route 202/206 North, Suite 301, Bridgewater, NJ, USA, 08807
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Executives
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Mutya Harsch officer: Chief Legal Officer and GC C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Tyler Zeronda officer: Interim CFO C/O VYNE THERAPEUTICS, 520 U.S. HIGHWAY 22, SUITE 204, BRIDGEWATER NJ 08807
Andrew Saik officer: Chief Financial Officer 640 LEE ROAD, CHESTERBROOK PA 19087
Rex Bright director 5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart officer: Chief Scientific Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski director, officer: President and CEO C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley officer: Chief Commercial Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Anthony D Bruno director C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Hirsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Ilan Hadar officer: CFO and Country Manager C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003